Philips launches wearable, medical-grade health monitoring devices, HealthSuite Health app

Philips announced Monday the global launch of wearable, medical-grade health monitoring devices, including a health watch, connected scale, blood pressure monitor and thermometer, along with a fully integrated companion HealthSuite health app. The company noted that the products are "designed to help those at risk of chronic disease to start measuring, keep monitoring and stay motivated in creating sustainable behaviour change."

Specifically, the health watch continuously and automatically measures a range of health biometrics, such as heart rate, activity and sleep patterns. Meanwhile, the upper arm and wrist blood pressure monitors measure systolic and diastolic blood pressure and heart rate. Philips added that the body analysis scale measures weight, estimates body fat and calculates body mass index, while the ear thermometer measures body temperature in two seconds. The devices are intended to be used with the free HealthSuite health app, which features insight and tip cards that appear over time as more information is entered through the smart devices.  

Additionally, the company said it launched "the first in a series of personal health programmes," which provide "tailored support to people taking steps towards healthier habits." According to Philips, each programme includes connected health measurement devices, an app-based personalised programme and cloud-based data analysis. The programmes are built on the company's HealthSuite digital platform, which it said is "an open and secure, cloud-based platform that collects and analyses health and other data from multiple devices and sources."

Last September, Philips announced plans to unveil a series of personal health programmes designed to help people manage their health in "a new era [of] connected care for consumers, patients and health providers." Later that month, Philips and Radboud University's medical centre introduced a connected digital-health prototype app, initially focused on patients with type 1 diabetes.

To read more Top Story articles, click here.